Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Newbury Pharmaceuticals AB's Median PS Value or its related term are showing as below:
OSTO:NEWBRY's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.86 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Newbury Pharmaceuticals AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.48
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB Median PS Value Related Terms
Newbury Pharmaceuticals AB Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NEWBRY vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Newbury Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.124.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Median PS Value of kr0.00 as of Aug. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 557 companies in the Drug Manufacturers industry.
Is Newbury Pharmaceuticals AB's Median PS Value too high?
Newbury Pharmaceuticals AB's current Median PS Value is kr0.00. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 557 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 557 companies for Median PS Value. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Median PS Value is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Median PS Value is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Median PS Value is kr0.00. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Median PS Value is kr0.00 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
Median PS Value: kr0.00
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for OSTO:NEWBRY
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
